Working… Menu

Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03712943
Recruitment Status : Active, not recruiting
First Posted : October 19, 2018
Last Update Posted : February 3, 2021
Bristol-Myers Squibb
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute

Brief Summary:
The main purpose of this study is to test the safety, tolerable side effects, and determine the highest tolerable dose of the combination of Regorafenib and Nivolumab. Researchers want to find out if this combination of Regorafenib and Nivolumab can help people with metastatic colorectal cancer with mismatch repair (MMR) proficiency.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Metastatic Colorectal Cancer Colon Cancer Drug: Regorafenib Drug: Nivolumab Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 52 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Regorafenib and Nivolumab
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of Regorafenib and Nivolumab in Mismatch Repair (MMR) Proficient Advanced Refractory Colorectal Cancer
Actual Study Start Date : October 23, 2018
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : October 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Regorafenib and Nivolumab Combination - Escalation
Dose Escalation: To find the dose of regorafenib that can be safely given with nivolumab in patients with advanced, refractory colorectal cancers.
Drug: Regorafenib
Regorafenib orally 80 mg daily for 21 days (3 weeks on, 1 week off).
Other Name: Stivarga

Drug: Nivolumab
Nivolumab 240 mg administered intravenously every 2 weeks.
Other Name: OPDIVO

Experimental: Regorafenib and Nivolumab Combination - Expansion
Dose Expansion: To find the effect on tumor of the combination of regorafenib and nivolumab.
Drug: Regorafenib
Regorafenib orally 80 mg daily for 21 days (3 weeks on, 1 week off).
Other Name: Stivarga

Drug: Nivolumab
Nivolumab 240 mg administered intravenously every 2 weeks.
Other Name: OPDIVO

Primary Outcome Measures :
  1. Maximum Tolerated Dose [ Time Frame: Up to 12 months ]
    To determine the maximum tolerated dose of Regorafenib in combination with Nivolumab in advanced, refractory colorectal cancers.

Secondary Outcome Measures :
  1. Response Rate [ Time Frame: Every 2nd cycle (Cycles are 28 days) up to 12 months ]
    To access response rate using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria

  2. Overall Survival (OS) [ Time Frame: Up to 24 months after conclusion of treatment ]
    Occurrence of Overall Survival

  3. Frequency and Severity of Adverse Events [ Time Frame: Up to 12 months ]
    To evaluate the frequency and severity of adverse events and tolerability of the combination regimen.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed diagnosis of colorectal adenocarcinoma
  • Proficient DNA mismatch repair (MMR) or stable microsatellite disease.
  • Participants with the presence of at least one lesion with measurable disease as defined by 10mm in longest diameter for a soft tissue lesions or 15mm in short axis for a lymph node by RECIST 1.1 for response assessment.
  • Participants must have received and progressed through or become intolerant to fluoropyrimidine, irinotecan, oxaliplatin, and bevacizumab, and if K-ras wild type, cetuximab or panitumumab containing therapies. Exceptions may apply.
  • Eastern Cooperative Oncology Group (ECOG) Performance Score 0 or 1
  • Estimated life expectancy over 3 months.
  • Adequate bone marrow, liver and renal function.
  • Participants must not have had chemotherapy, major surgery, monoclonal antibody therapy or experimental therapy within the 21 days prior to the start of regorafenib and nivolumab administration
  • Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) performed within 24 hours prior to the start of study drug and then every 4 weeks. Post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test.
  • Participants (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the Informed Consent Form (ICF) until at least 5 months for females and 7 months for males after the last dose of study drug
  • Participants must be able to understand and be willing to sign the written informed consent form and be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other study requirements.

Exclusion Criteria:

  • Participants with active Central Nervous System (CNS) metastases If CNS metastases are treated and participants are at neurologic baseline for at least 2 weeks prior to enrollment, they will be eligible but will need a Brain MRI prior to enrollment.
  • Uncontrolled hypertension (systolic pressure >140 mm Hg or diastolic pressure > 90 mm Hg [NCI-CTCAE v5.0] on repeated measurement) despite optimal medical management.
  • Active or clinically significant cardiac disease.
  • Women who are pregnant or breast-feeding
  • Prior therapy with regorafenib, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways).
  • Previous or concurrent cancer within 3 years prior to treatment start EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer, superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina propria)].
  • Active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  • Ascites, pleural effusion, or pericardial fluid requiring drainage in the last 4 weeks
  • Participants with phaeochromocytoma
  • Ongoing infection > Grade 2
  • Presence of a non-healing wound, or bone fracture.
  • Renal failure requiring hemo-or peritoneal dialysis.
  • Seizure disorder requiring medication.
  • Interstitial lung disease with ongoing signs and symptoms at the time of informed consent.
  • Pleural effusion or ascites that causes respiratory compromise.
  • Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation.
  • Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial.
  • Persistent proteinuria ≥ Grade 3
  • History of organ allograft
  • Participants requiring warfarin or equivalent vitamin K antagonists (e.g. phenprocoumon)
  • Participants with a condition requiring a strong CYP3A4 inhibitors or strong CYP3A4 inducers.
  • Unresolved toxicity higher than CTCAE grade 1 attributed to any prior therapy or procedure, excluding alopecia.
  • Any hemorrhage or bleeding event ≥ NCI CTCAE Grade 3 within 4 weeks prior to start of study medication.
  • Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
  • Participants with an arterial thrombotic or thromboembolic event within 6 months of informed consent.
  • Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection.
  • Child-Pugh B cirrhosis (or worse) or a history of hepatic encephalopathy
  • History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
  • Major surgery or a wound that has not fully healed within 4 weeks of enrollment.
  • Participants requiring concurrent anti-cancer therapy other than study treatment.
  • Participants requiring hormonal therapy during the study or within 2 weeks of first study enrollment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03712943

Layout table for location information
United States, Florida
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States, 33612
Sponsors and Collaborators
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb
Layout table for investigator information
Principal Investigator: Dae W Kim, MD H. Lee Moffitt Cancer Center and Research Institute
Layout table for additonal information
Responsible Party: H. Lee Moffitt Cancer Center and Research Institute Identifier: NCT03712943    
Other Study ID Numbers: MCC-19581
First Posted: October 19, 2018    Key Record Dates
Last Update Posted: February 3, 2021
Last Verified: February 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by H. Lee Moffitt Cancer Center and Research Institute:
colon cancer
Mismatch Repair
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Colonic Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents